Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) - Heinemann, V; Fischer von Weikersthal, L; Decker, T (2013)
ASCO Annual Meeting (Abstract No. LBA3506)